COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804


Print ISSN:-2581-4710

Online ISSN:-2581-4729

CODEN : IIJCBS

Current Issue

Year 2020

Volume: 6 , Issue: 1

Article Access statistics

Viewed: 534

Emailed: 0

PDF Downloaded: 199

IP Indian Journal of Clinical and Experimental Dermatology


Cyclosporine - An eye opener in severe cutaneous adverse drug reactions


Full Text PDF Share on Facebook Share on Twitter


Author Details : V. Anandan, P.S. Mohana Sundari, Yoga Nandhini, Ragini Rajan

Volume : 4, Issue : 1, Year : 2018

Article Page : 48-53


Suggest article by email

Abstract

Severe cutaneous adverse drug reactions (sCADR) comprise the life-threatening Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Aim: The aim of this study was to assess the efficacy and safety of cyclosporine in treating sCADR.
Materials and Methods: A retrospective study was done from data collected over a three year period at the department of dermato-venereo-leprology at a tertiary care centre in South India. Out of thirty-four in-patients with adverse drug reactions (ADRs), twenty who fulfilled the inclusion criteria (one DRESS, ten SJS and nine TEN patients) were taken for the study. Fixed drug eruption and TEN with multiorgan failure were excluded.
Methodology: Patients were evaluated, screened for multiorgan involvement, offending drug/drugs were withheld, routine investigations done and the severity assessed based on SCORTEN. Treatment was initiated with injection dexamethasone 1mg/kg/day and supportives. In those with unsatisfactory response in three days, if not contra-indicated, oral cyclosporine was added at a dose of 100mg bid for 2 weeks, tapered by 50mg/week and stopped once the lesions healed. Efficacy of cyclosporine was assessed using the average number of stabilization days, the rate of cutaneous re-epithelialization and the duration of hospitalization.
Results: For SJS, the mean duration of stabilization was 2 days, re-epithelialization 7.9 days and hospital-stay 18.1 days. For TEN, the mean duration of stabilization was 3.9 days, re-epithelialization 12.8 days and hospital-stay 29.2 days.
Conclusion: With the use of cyclosporine, patients stabilized early, re-epithelialization occurred early; concomitant use with steroids helped in early tapering of steroid dose. Recovery time and duration of hospital stay were shortened. Cyclosporine was well tolerated, no significant toxicity was noted; there was no mortality.

Keywords: Cyclosporine, Severe cutaneous adverse drug reactions, DRESS, SJS, TEN.

Doi : 10.18231/.2018.0011

How to cite : Anandan V, Sundari P M, Nandhini Y, Rajan R, Cyclosporine - An eye opener in severe cutaneous adverse drug reactions. IP Indian J Clin Exp Dermatol 2018;4(1):48-53

Copyright © 2018 by author(s) and IP Indian J Clin Exp Dermatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)